norelgestromin / ethinyl estradiol

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Evra. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Evra.

For practical information about using Evra, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 09/11/2022

Authorisation details

Product details
Agency product number
Active substance
  • norelgestromin
  • ethinyl estradiol
International non-proprietary name (INN) or common name
  • norelgestromin
  • ethinyl estradiol
Therapeutic area (MeSH)
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Gedeon Richter Plc.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Gyomroi ut 19-21
1103 Budapest

Product information

09/11/2022 Evra - EMEA/H/C/000410 - IB/0053

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Sex hormones and modulators of the genital system

Therapeutic indication

Female contraception.

Evra is intended for women of fertile age. The safety and efficacy has been established in women aged 18 to 45 years.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating